Garry A. Neil to Speak at Upcoming Investor Conferences
Avalo Therapeutics, Inc. (NASDAQ: AVTX) is making headlines with its participation in significant investor conferences slated for the coming months. The spotlight will be on Garry A. Neil, M.D., the Chief Executive Officer and Chairman of the Board, who is set to share insights and significant developments regarding the company’s innovative approaches to treating immune dysregulation.
Details of the Conferences
The first event is the highly anticipated Stifel 2024 Healthcare Conference, where Dr. Neil will present on Monday, November 18, 2024, at 3:35 PM ET. Following that, he will also take part in the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 5, 2024, at 11:00 AM ET.
Accessing the Presentations
For those unable to attend these conferences in person, Avalo Therapeutics will offer live webcasts featuring Dr. Neil’s presentations. Interested parties can find the webcasts and replays in the Investors section under "News / Events" on the Avalo Therapeutics website. These archived sessions will be accessible for a minimum of 30 days, ensuring that stakeholders can stay informed about Avalo's progress and insights.
About Avalo Therapeutics and Its Mission
Avalo Therapeutics, founded with a primary focus on clinical stage biotechnology, is dedicated to advancing treatments for immune dysregulation. At the forefront of Avalo's research is its lead asset, AVTX-009, a groundbreaking anti-IL-1? monoclonal antibody designed to combat inflammatory diseases.
Innovative Therapeutics
Avalo Therapeutics' product lineup includes innovative drug candidates such as quisovalimab (an anti-LIGHT mAb) and AVTX-008 (a BTLA agonist fusion protein). These candidates aim to provide targeted solutions for patients suffering from various autoimmune and inflammatory conditions.
Understanding AVTX-009
AVTX-009 stands out as a humanized monoclonal antibody with specific affinity for interleukin-1? (IL-1?), a pivotal molecule in the inflammation cascade. Elevated or poorly regulated levels of IL-1? are linked to numerous autoimmune and inflammatory diseases. By inhibiting IL-1? activity, AVTX-009 may offer therapeutic benefits for conditions such as hidradenitis suppurativa, among others in the fields of dermatology, gastroenterology, and rheumatology.
Inquiries for Investors and Media
For any inquiries regarding investor relations or media questions, Christopher Sullivan, CFO of Avalo Therapeutics, is available for contact. Interested individuals can reach out via email or phone, with his contact details provided: ir@avalotx.com and 410-803-6793.
Additionally, inquiries can also be directed to Meru Advisors, represented by Lauren Glaser, at lglaser@meruadvisors.com.
Frequently Asked Questions
What is Avalo Therapeutics known for?
Avalo Therapeutics is a clinical stage biotechnology company focusing on treatments for immune dysregulation, particularly through its innovative drug candidates.
Who will present at the investor conferences?
Dr. Garry A. Neil, the CEO and Chairman of Avalo Therapeutics, will lead the presentations at the upcoming healthcare conferences.
When are the upcoming conferences?
The Stifel 2024 Healthcare Conference is scheduled for November 18, 2024, and the Piper Sandler 36th Annual Healthcare Conference will take place on December 5, 2024.
How can I access the conference presentations?
The live webcasts and replays of the presentations will be available on the Avalo Therapeutics website under the Investors section.
What is AVTX-009?
AVTX-009 is a humanized monoclonal antibody that targets interleukin-1?, which plays a significant role in the inflammatory process related to various autoimmune and inflammatory diseases.